US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

登録

BMY Bristol Myers Squibb Co

48.93

0.63 (1.30%)

取引時間後

最終更新日： 07:35:22

Bristol-Myers Gets Europe OK for Sprycel in Form of Leukemia

   By Colin Kellaher

Bristol-Myers Squibb Co. (BMY) on Monday said the European Commission approved the company's Sprycel in combination with chemotherapy for children with a form of leukemia.

The New York biopharmaceutical company said the approval covers the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia and includes both the tablet and powder formulations.

Bristol-Myers said the approval marks the second pediatric leukemia indication for Sprycel in Europe.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

February 11, 2019 07:32 ET (12:32 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Bristol Myers Squibb (NYSE:BMY)
過去株価チャート
から 3 2024 まで 4 2024

Bristol Myers Squibbのチャートをもっと見るにはこちらをクリック

Bristol Myers Squibb (NYSE:BMY)
過去株価チャート
から 4 2023 まで 4 2024

Bristol Myers Squibbのチャートをもっと見るにはこちらをクリック

ニュース - Bristol-Myers Squibb Company

KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
火曜日 9年4月2024日 (2週前) • Business Wire

Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
日曜日 7年4月2024日 (2週前) • Business Wire

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
金曜日 5年4月2024日 (2週前) • Business Wire

European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
水曜日 3年4月2024日 (2週前) • Business Wire

Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
火曜日 2年4月2024日 (3週前) • Business Wire

Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…
金曜日 29年3月2024日 (3週前) • Business Wire

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
金曜日 29年3月2024日 (3週前) • Business Wire

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
木曜日 28年3月2024日 (3週前) • GlobeNewswire Inc.

A Bristol Myers Squibb Expande as Iniciativas de Doações para a Equidade em Saúde a fim de Melhorar os Resultados de Saúde
水曜日 27年3月2024日 (3週前) • Business Wire

Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
火曜日 26年3月2024日 (4週前) • Business Wire

Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
月曜日 25年3月2024日 (4週前) • Business Wire

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
木曜日 21年3月2024日 (1月前) • Business Wire

その他のBristol-Myers Squibb Companyニュース記事

Verizon Communications

BNP Paribas (QX)

Health Care Select Sector

Bank of America

US Dollar vs Euro

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約